Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.43 |
| ▸ | SOD1 | P00441 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 4/20 | 0.36 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 2/20 | 0.34 |
| ▸ | MGLL | Q99685 | 1/20 | 0.32 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.32 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13400000 | 0.82 | ALDH1A1 (0.57) | ALDH1A1MAPTSCN9ASOD1TSHR | |
| SCHEMBL2797613 | 0.80 | MAPT (0.78) | ALDH1A1MAPTSCN9ASOD1TSHR | |
| SCHEMBL21916107 | 0.79 | SCN9A (0.40) | SCN9ASOD1 | |
| SCHEMBL6352538 | 0.79 | MAPT (0.53) | ALDH1A1MAPTSCN9ASOD1TSHR | |
| SCHEMBL23061347 | 0.77 | SCN9A (0.41) | ALDH1A1SCN9ASOD1 | |
| SCHEMBL27632817 | 0.76 | SCN9A (0.42) | ALDH1A1MAPTSCN9ANR2E1 | |
| SCHEMBL27632839 | 0.76 | SCN9A (0.42) | ALDH1A1MAPTSCN9ANR2E1 | |
| SCHEMBL1603516 | 0.76 | MAPT (0.50) | ALDH1A1MAPTSCN9ASOD1TSHR | |
| SCHEMBL5866793 | 0.76 | MAPT (0.50) | ALDH1A1MAPTSCN9ASOD1TSHR | |
| SCHEMBL1264065 | 0.76 | ALDH1A1 (0.50) | ALDH1A1MAPTSCN9ASOD1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1921078-B1 | MULTIKINASE INHIBITOR | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2013-01-09 | — | — | EP | disclosed |
| US-8299252-B2 | Pyrazolopyridine and pyrrolopyridine multikinase inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-10-30 | — | — | US | disclosed |
| US-8299252-B2 | Pyrazolopyridine and pyrrolopyridine multikinase inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-10-30 | — | — | US | disclosed |
| US-8299252-B2 | Pyrazolopyridine and pyrrolopyridine multikinase inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-10-30 | — | — | US | disclosed |
| US-20100168430-A1 | MULTIKINASE INHIBITOR | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-07-01 | — | — | US | disclosed |
| US-20100168430-A1 | MULTIKINASE INHIBITOR | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-07-01 | — | — | US | disclosed |
| US-20100168430-A1 | MULTIKINASE INHIBITOR | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-07-01 | — | — | US | disclosed |
| EP-1921078-A1 | MULTIKINASE INHIBITOR | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-05-14 | — | — | EP | disclosed |
| EP-1921078-A1 | MULTIKINASE INHIBITOR | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168430-A1 | MULTIKINASE INHIBITOR | REN, RAF1, CHUK | ALDH1A1 2482/4885MAPT 3296/4885SCN9A 3009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.